AstraZeneca earnings hit by waning cholesterol drug sales
 

AstraZeneca earnings hit by waning cholesterol drug sales

LONDON (Reuters) – Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter earnings down by nearly a third at drugmaker AstraZeneca, which is **w banking on new cancer medicines to revive its fortunes.http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA [IMG]http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:F7zBnMyn0Lo[/IMG] [IMG]http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:V_sGLiPBpWU[/IMG]
[IMG]http://feeds.feedburner.com/~r/reuters/businessNews/~4/YLXebch**dU[/IMG]